Clínica Universidad de Navarra, Madrid

Cancer Center Director

Co-director Oncology Department

Head Medical Oncology

GEICO President

Grupo Español Investigación Cáncer Ovario

ENGOT Chairman 2018-2020

European Network for Gynaecological Oncological Trials

Antonio González-Martín, graduated in medicine from the University of Navarra in Pamplona, Spain, and subsequently trained in medical oncology at University Hospital Ramón y Cajal in Madrid, Spain, from 1994 to 1997. During part of 1997, he attended as an observer at Mount Sinai School of Medicine in New York, New York, United States.

Dr González-Martín joined as a staff member of the Medical Oncology Service at University Hospital Ramón y Cajal, Madrid, in 1998. In January 2009, he gained the position of head of the Medical Oncology Department at MD Anderson Cancer Center Madrid, Spain, an affiliate institution of MD Anderson Cancer Center in Houston, Texas, United States. In September 2017, he moved to Clínica Universidad de Navarra in Madrid, Spain, as head of medical oncology and co-director of the Oncology Department. Currently he is the director of the Cancer Centre Universidad de Navarra in Spain. He is also an associate professor of medicine at Francisco de Vitoria University in Madrid, Spain, where he obtained the PhD.

Dr González-Martín specializes in the treatment of gynaecologic and breast cancer. He is the chairman of GEICO (Spanish group for investigation in ovarian and gynaecological cancer), the GEICO representative in ENGOT (European Network for Gynecological Oncological Trials), and one of the representatives of GEICO in the Gynecologic Cancer InterGroup. He also served as the chair of the ovarian cancer committee in GCIG for the period 2016-2020, and as the chairman of ENGOT for the period 2018-2020. In addition, Dr González-Martín is a member of the board of the Spanish Society of Medical Oncology (SEOM) and he is also Associate Editor of International Journal of Gynecological cancer.

Dr González-Martín has several relevant publications in the field of gynecologic and breast cancer. The five most relevant in the last years are listed below.

Banerjee S, Gonzalez-Martin A, Harter P, Lorusso D, Moore KN, Oaknin A, Ray-Coquard I. First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open – Cancer Horizons round-table discussion. ESMO Open. 202 Nov;5(6):e001110. doi: 10.1136/esmoopen-2020-001110. PMID: 33310779; PMCID: PMC7783599.

Mirza MR, Coleman RL, González-Martín A, Moore KN, Colombo N, Ray-Coquard I, Pignata S. The forefront of ovarian cancer therapy: update on PARP inhibitors. Ann Oncol. 2020 Sep;31(9):1148-1159. doi: 10.1016/ j.annonc. 2020.06.004. Epub 2020 Jun 20. PMID: 32569725.

Concin N, Creutzberg CL, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann JA, Bosse T, Chargari C, Fagotti A, Fotopoulou C, González-Martín A, Lax SF, Lorusso D, Marth C, Morice P, Nout RA, O’Donnell DE, Querleu D, Raspollini MR, Sehouli J, Sturdza AE, Taylor A, Westermann AM, Wimberger P, Colombo N, Planchamp F, Matias-Guiu X. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. Virchows Arch. 2021 Feb;478(2):153-190. doi: 10.1007/s00428-020-03007-z. PMID: 33604759.

González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O’Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ; PRIMA/ENGOT-OV26/GOG-3012 Investigators.Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28.

Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi:10.1056/NEJMoa1911361

Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, Raspagliesi F, Sonke GS, Birrer M, Provencher DM, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger PB, Rudaitis V, Katchar K, Wu H, Keefe S, Ruman J, Ledermann JA. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019 Jul 1;30(7):1080-1087. doi: 10.1093/annonc/mdz135.

Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N  Engl J Med. 2018 Oct 21. doi: 10.1056/NEJMoa1810858. [Epub ahead of print] PubMed PMID: 30345884.

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016 Dec 1;375(22):2154-2164.